Alcobra Ltd. to Present at 27th Annual ROTH Conference

TEL AVIV, Israel, March 3, 2015 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq: ADHD), an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced that Dr. Yaron Daniely, President and Chief Executive Officer of Alcobra, will provide a corporate overview at the 27th Annual ROTH Conference.

About Alcobra Ltd.

Alcobra Ltd. is an emerging pharmaceutical company primarily focused on the development and commercialization of a proprietary drug candidate, MDX, to treat cognitive disorders including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome. MDX has completed multiple Phase II studies and a Phase III study in adults with ADHD. The company is conducting separate Phase II trials in pediatric ADHD and in Fragile X Syndrome. For more information please visit the Company's website, www.alcobra-pharma.com, the content of which is not incorporated herein by reference.

CONTACT: U.S. Investor Contacts
         LifeSci Advisors, LLC
         Michael Rice
         646-597-6979
         [email protected]

         Media Inquiries
         Sam Brown, Inc.
         Mike Beyer
         773-463-4211
         [email protected]

         Israel Investor Contact:
         Alcobra Investor Relations
         Debbie Kaye
         +972-72 2204661
         [email protected]

You May Also Be Interested In

• Aarion Capital LP Marks Six Months Since Launch With Inaugural Performance Report and Continued Institutional Development
• CONDITIONS FOR SALE OF RIKSBANK CERTIFICATES
• Arvulonikanz Reviews: Is Arvulonikanz AI Trading Platform Worth It?